New report unveils hidden cost of Alzheimer’s disease, with cases to double by 2050

“It’s important to acknowledge the size of the issue and enormity of the challenge. Approximately 880,000 Australians are now living with a severe and complex mental illness,” said Dirk Otto, the general manager of Boehringer Ingelheim Australia

New Zealand's Pharmac has announced that from 1 November, it will expand access to Merck's ERBITUX (cetuximab) for bowel cancer, bendamustine for blood cancer, and pemetrexed.

A recent heart screening program delivered by Shane Warne Legacy in partnership with Novartis, SiSu Health, and Wesfarmers has highlighted the critical role of accessible heart screening programs in improving health outcomes for those living in rural and regional areas of Australia.

The Australian researchers and industry leaders were recognised for discovering a GSK-commercialised drug that started its development at Melbourne-based company Cytopia.

Telix has announced that the TGA has approved the use of Illuccix to select patients for PSMA-targeted radionuclide therapy.

Healthy Bones Australia is teaming up with an Olympian, doctors, politicians, and patients today to launch findings from a national burden of disease report.

Anyone wanting to understand how the proposed streamlined process for cost-minimised therapies could walk need only look to New Zealand.

The inaugural 'Wesfarmers Health: Australia's Health Index' reveals that the country's health debt remains significant following the COVID-19 pandemic.

In the leadup to World Arthritis Day, 11 health and allied peak bodies have aligned in a broad-based push to reduce critical delays in diagnosing the painful childhood illness Juvenile Arthritis, signing a consensus statement to be released at a National Stakeholder Forum in Parliament House today.

Is it a case of 'The Emperor's New Clothes'? Does the 19th-century folktale about the foolishness of failing to speak up for the truth and what is right provide a valuable lesson?

A new report commissioned by GSK has revealed that increasing investment in adult immunisation could deliver $1.1 billion in benefits every year.

“No child and family suffering through a high-risk neuroblastoma diagnosis will have to worry about receiving the world’s best treatment," said Health Minister Mark Butler.

CSL Seqirus has welcomed the recent PBS listing of VAZKEPA (icosapent ethyl) for statin-treated patients with elevated triglycerides and at high risk of heart attack and stroke.

It appears that PBS spending is in a growth phase. New listings could be a contributing factor, but the real driver is a 22 million increase in prescriptions dispensed at no cost to patients.

A significant structural change in the PBS, which the Government attempted to blunt with 60-day dispensed quantities, is arguably the main growth driver in spending on the program. We discuss the change, which along with others, represents a major reversal in a decades-long approach to medicines access.

Australian women want more accurate information about their contraceptive choices, with 70 per cent believing they have insufficient education on contraception.

Rare disease company Swedish Orphan Biovitrum, Sobi, has announced the appointment of Chloé Pérot as its general manager for Australia and New Zealand.

Otsuka Australia’s employees have marked the company’s 10th anniversary in Australia with celebrations hosted by local managing director Soonhee Park and attended by senior executives from Japan.

Health Minister Mark Butler and the Pharmaceutical Benefits Advisory Committee are currently 'considering' what next on the health technology assessment review.